Business Wire

BALDERTON-CAPITAL

7.2.2020 13:03:07 CET | Business Wire | Press release

Share
Balderton Capital, Europe’s Most Active Series A Investor, Welcomes Two New General Partners

Balderton Capital announces today that it has hired two new General Partners. Rana Yared joins from Goldman Sachs, where she was Partner in the Principal Strategic Investments team. David Thévenon joins from SoftBank’s Vision Fund, where he was one of the initial Partners.

Bernard Liautaud, Managing Partner of Balderton Capital, said: "I am delighted to welcome Rana and David to the partnership. They both bring outstanding experience in investing globally in the technology ecosystem. With her team at Goldman Sachs, Rana has built one of the best fintech and AI portfolios across the US and Europe. And within Softbank, David has participated in the growth journeys of companies as diverse as Didi in China, Grab in Singapore, Lemonade and SoFi in the US. The opportunity in the European tech ecosystem continues to expand at a rapid pace, and Rana and David will play a key role in our investment strategy in the European venture space."

During her time at Goldman Sachs, Rana’s team invested $2bn in 80 companies, with a strong focus on fintech. As one of Goldman’s best-known tech investors, Rana led the US and European Principal Strategic Investment (PSI) teams and served on Goldman’s Growth Equity Investment committee. She spent five years on the board of the fixed income trading platform Tradeweb, until it went public in April 2019 with a market capitalisation of $6bn. Rana also brought the artificial intelligence platform Kensho to Goldman Sachs. Kensho was ultimately sold to S&P Global for $550m in March 2018.

Rana currently sits on the boards of Nutmeg, Vestwell, NAV, Pensando, Digital Reasoning, Veem, and NYSHEX. She joined Goldman Sachs as an analyst in 2006 and was named Managing Director in 2013 and Partner in 2018.

Rana Yared said: “My greatest passion is working closely with founders and their teams to build new companies, and I am delighted to be able to devote myself to this when I join Balderton. In recent years, Europe has established itself as a tech leader and is brimming with potential and opportunity. I am excited to move back to the European side of the Atlantic and to begin seeking out and working with the next generation of exciting tech companies.”

During his five-year tenure at SoftBank, David led investments in Didi Chuxing, the world's leading mobile transportation platform; Grab, Southeast Asia's leading superapp; Ola, India's leading ride-sharing platform; Lemonade, the digital insurance company powered by AI and driven by social good; SoFi, the American online personal finance platform; and Kabbage, one of the leading US SMB lending platforms. David was also involved in SoftBank's investments in 99 in Brazil (bought by Didi) and Legendary Pictures in the US (sold to Wanda Group).

Before joining SoftBank, David had a 10-year career at Google, where he worked on partnerships for products that touched billions of users, including leading global product and business partnerships for Google's Android platform.

David Thévenon said: “Five years ago I left Google to focus on venture investing at SoftBank and I felt privileged to meet, invest and work with some of the most innovative and visionary founders, supporting them as they grew into market-leading companies. Joining Balderton will allow me to continue this for European-founded companies, and I am truly excited about the opportunity ahead.”

[ENDS]

About Balderton:
Balderton Capital is a London-based venture firm focused exclusively on backing the best European-founded technology companies. In the two decades since our founding, we have worked with hundreds of extraordinary European founders, and have raised eight funds totalling more than $3bn. Balderton’s most recent funds were the early-stage Balderton VII, raised in November 2019, and Liquidity I, Europe’s first venture fund dedicated to secondary investments in European-founded, growth-stage technology startups, raised in October 2018. Previous exited investments include Betfair (FTSE: BET), Magic Pony (Twitter), NaturalMotion (Zynga), Recorded Future (Insight Partners), Sunrise (Microsoft), Talend (NASDAQ: TLND) and Yoox Net-a-Porter (BIT: YNAP). Among Balderton’s current portfolio of over 90 companies are Aircall, Carwow, Citymapper, Contentful, Darktrace, Depop, GoCardless, The Hut Group, Kobalt Music, Nutmeg, Peakon, Prodigy Finance, Revolut, SOPHiA Genetics, Tessian, Vestiaire Collective, Vivino, Voi Technology, and Zego.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 07:00:00 CEST | Press release

H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the

Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 04:00:00 CEST | Press release

Milestone-based government program supports multiple fusion approaches toward power demonstration and commercialization Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated ove

Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28[1]31.8.2026 23:35:00 CEST | Press release

ITC Infotech Board approves proposed acquisition of 22.1% promoter stake and a Scheme of Amalgamation of the two companies ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will syner

Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 21:07:00 CEST | Press release

Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu

BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 21:00:00 CEST | Press release

Agreement advances patient access and strengthens BeOne's long-term commitment to U.S. innovation and manufacturing BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional res

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye